Auriga et al. invest €5m in Fab'entech

The company will use the funding to accelerate international expansion, with a particular focus on Australia and Asia.

Fab'entech will also begin expanding its product pipeline to cover a larger range of pathogens and plans on building a production site in the Lyon Gerland Biodistrict, which it hopes will be operational by 2016.

Rhône-Alpes invested on its own and via the R2V fund, a joint vehicle with Viveris Management that had raised €25m in February.

Auriga is believed to have invested via its €40m Auriga IV Bioseeds fund.

Company
Founded in 2009 and based in Lyon, Fab'entech develops passive immunotherapeutic solutions for emerging infectious diseases, based on the F(ab')₂ polyclonal immunoglobulins. Diseases being targeted by Fab'entech include H5N1 avian flu, Ebola virus and Sars.

The company currently has one commercially available product, Fabenflu, which is a passive immunotherapy for post-exposure to H5N1 avian flu. Its anti-Crimean-Congo Hemorrhagic Fever (CCHF) product is currently in pre-clinical stage, and its anti-Hendra and anti-Nipah virus therapies are currently in proof-of-concept stage.

The company employs 10 staff.

People
Bertrand Lépine is the president and founder of Fab'entech. Auriga partner Franck Lescure worked on the deal alongside Rhône-Alpes and R2V senior associate Mathieu Viallard and Sigma investment director Guillaume Hemmerlé.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France